Statin therapy in COVID-19 infection: much more than a single pathway.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

28 citing papers in PubMed.

1. Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled trial.Respiratory research · 2024
   Trial
2. Predictors of pulmonary embolism in hospitalized patients with COVID-19.Thrombosis journal · 2023
   Article
3. Survival impact of previous statin therapy in patients hospitalized with COVID-19.Medicina clinica (English ed.) · 2023
   Article
4. [Survival impact of previous statin therapy in patients hospitalized with COVID-19].Medicina clinica · 2023
   Article
5. Role of Lactone and Acid Forms in the Pleiotropic Effects of Statins.Pharmaceutics · 2022
   Article
6. In Vitro Evidence of Statins' Protective Role against COVID-19 Hallmarks.Biomedicines · 2022
   Article
7. Atorvastatin for reduction of 28-day mortality in hospitalized COVID-19 patients: study protocol for a randomized, double-blinded, placebo-controlled, clinical trial.Trials · 2022
   Article
8. Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study.Frontiers in cardiovascular medicine · 2022
   Article
9. Impact of Working from Home on Cardiovascular Health: An Emerging Issue with the COVID-19 Pandemic.International journal of environmental research and public health · 2021
   Review
10. Direct Activation of Endothelial Cells by SARS-CoV-2 Nucleocapsid Protein Is Blocked by Simvastatin.Journal of virology · 2021
    Article
11. Metabolic Reprogramming in COVID-19.International journal of molecular sciences · 2021
    Review
12. Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review.Journal of infection and public health · 2021
    Review
13. Statins in COVID-19 Therapy.Life (Basel, Switzerland) · 2021
    Review
14. Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome.Cells · 2021
    Review
15. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor.Pharmacology & therapeutics · 2021
    Review
16. Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets.Progress in lipid research · 2021
    Review
17. Adjunctive Use of Statins for COVID-19.Journal of clinical medicine · 2021
    Article
18. Drugmonizome and Drugmonizome-ML: integration and abstraction of small molecule attributes for drug enrichment analysis and machine learning.Database : the journal of biological databases and curation · 2021
    Article
19. Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment.Atherosclerosis · 2021
    Review
20. Direct activation of endothelial cells by SARS-CoV-2 nucleocapsid protein is blocked by Simvastatin.bioRxiv : the preprint server for biology · 2021
    Article

Corrections and comments

• Comment on
  Statin therapy in COVID-19 infection.2020

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as